115 Publications (Page 1 of 5)
2021
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
Clark, Joseph ICurti, BrendanDavis, Elizabeth JKaufman, HowardAmin, AsimLogan, Theodore FHauke, RalphMiletello, Gerald PVaishampayan, UlkaJohnson, Douglas BWhite, Richard LWiernik, Peter H and Dutcher, Janice P
Journal of Investigative Medicine, vol. 69, (no. 4), pp. 888-892, Apr 2021. | Journal Article
2020
Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003
Dudek, Arkadiusz ZDudek, A.Z.Liu, Li CLiu, L.C.Gupta, ShilpaGupta, S.Logan, Theodore FLogan, T.F.Singer, Eric ASinger, E.A.Joshi, M.Joshi, MonikaZakharia, Y.N.Zakharia, Yousef NLang, Joshua MLang, J.M.Schwarz, James KSchwarz, J.K.Al-Janadi, AnasAl-Janadi, A.Alva, Ajjai S and Alva, A.S.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, (no. 11), pp. 1145, 2020-Apr-10. | Journal Article
 
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma
Timmerman, JohnTimmerman, JohnHerbaux, CharlesHerbaux, CharlesRibrag, VincentRibrag, VincentZelenetz, Andrew DZelenetz, Andrew DHouot, RochHouot, RochNeelapu, Sattva SNeelapu, Sattva SLogan, TheodoreLogan, TheodoreLossos, Izidore SLossos, Izidore SUrba, WalterUrba, WalterSalles, GillesSalles, GillesRamchandren, RadhakrishnanRamchandren, RadhakrishnanJacobson, CaronJacobson, CaronGodwin, JohnGodwin, JohnCarpio, CeciliaCarpio, CeciliaLathers, DeanneLathers, DeanneLiu, YaliLiu, YaliNeely, JaclynNeely, JaclynSuryawanshi, SatyendraSuryawanshi, SatyendraKoguchi, YoshinobuKoguchi, YoshinobuLevy, Ronald and Levy, Ronald
American Journal of Hematology, vol. 95, (no. 5), pp. 520, May 2020. | Journal Article
2019
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma
Voss, Martin HVoss, Martin HBhatt, Rupal SBhatt, Rupal SVogelzang, Nicholas JVogelzang, Nicholas JFishman, MayerFishman, MayerAlter, Robert SAlter, Robert SRini, Brian IRini, Brian IBeck, J TBeck, J TJoshi, MonikaJoshi, MonikaHauke, RalphHauke, RalphAtkins, Michael BAtkins, Michael BBurgess, EarleBurgess, EarleLogan, Theodore FLogan, Theodore FShaffer, DavidShaffer, DavidParikh, RahulParikh, RahulZhang, XiaoshaZhang, XiaoshaGlasser, ChadGlasser, ChadSherman, Matthew LSherman, Matthew LPlimack, Elizabeth R and Plimack, Elizabeth R
Cancer, vol. 125, (no. 14), pp. 2400-2408, Jul 2019. | Journal Article
 
Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients
Pili, RobertoPili, RobertoPili, RobertoPili, RobertoPili, RobertoPili, RobertoQuinn, David IQuinn, David IQuinn, David IQuinn, David IQuinn, David IQuinn, David IAlbany, CostantineAlbany, CostantineAlbany, CostantineAlbany, CostantineAlbany, CostantineAlbany, CostantineAdra, NabilAdra, NabilAdra, NabilAdra, NabilAdra, NabilAdra, NabilLogan, Theodore FLogan, Theodore FLogan, Theodore FLogan, Theodore FLogan, Theodore FLogan, Theodore FGreenspan, AndrewGreenspan, AndrewGreenspan, AndrewGreenspan, AndrewGreenspan, AndrewGreenspan, AndrewBudka, JustinBudka, JustinBudka, JustinBudka, JustinBudka, JustinBudka, JustinDamayanti, NurDamayanti, NurDamayanti, NurDamayanti, NurDamayanti, NurGreen, Mark AGreen, Mark AGreen, Mark AGreen, Mark AGreen, Mark AGreen, Mark AFletcher, James WFletcher, James WFletcher, James WFletcher, James WFletcher, James WFletcher, James WTann, MarkTann, MarkTann, MarkTann, MarkTann, MarkTann, MarkEdwards, Sara IEdwards, Sara IEdwards, Sara IEdwards, Sara IEdwards, Sara IEdwards, Sara IBurney, HeatherBurney, HeatherBurney, HeatherBurney, HeatherBurney, HeatherBurney, HeatherLiu, HaoLiu, HaoLiu, HaoLiu, HaoLiu, HaoLiu, HaoHahn, Noah MHahn, Noah MHahn, Noah MHahn, Noah MHahn, Noah M and Hahn, Noah M
Journal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. 2572, 2019-05-20. | Journal Article
2018
A Clinically Suitable Approach to Whole-Body Imaging for Quantification of Regional Perfusion: Validation of Positron Emission Tomography (PET) with 62Cu-ETS and Image-based Tracer Kinetic Modeling
Cheng, MonicaCheng, MonicaSmith, Nathaniel JSmith, Nathaniel JTerrito, Wendy LTerrito, Wendy LMathias, Carla JMathias, Carla JFletcher, James WFletcher, James WLogan, Theodore FLogan, Theodore FGreen, Mark AGreen, Mark AHutchins, Gary D and Hutchins, Gary D
Proceedings of IMPRS, vol. 1, (no. 1), 2018-12-07. | Journal Article
 
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.
Clark, Joseph ISingh, JatinderErnstoff, Marc SLao, Christopher DFlaherty, Lawrence ELogan, Theodore FCurti, BrendanAgarwala, Sanjiv STaback, BretCranmer, LeeLutzky, JoseLuna, Theresa LAung, Sandra and Lawson, David H
Journal for immunotherapy of cancer, vol. 6, (no. 1), pp. 76, July 27, 2018. | Journal Article
 
Clinical features and survival outcomes in a prospective spontaneous regression (SR) protocol of renal cell carcinoma (RCC) and melanoma (M) patients
Gbolahan, Olumide BGbolahan, Olumide BGbolahan, Olumide BHashemi-Sadraei, NedaHashemi-Sadraei, NedaHashemi-Sadraei, NedaConteh, AbassConteh, AbassConteh, AbassKaimakliotis, Hristos ZKaimakliotis, Hristos ZKaimakliotis, Hristos ZStorkus, WalterStorkus, WalterStorkus, WalterPili, RobertoPili, RobertoPili, RobertoLogan, Theodore FLogan, Theodore F and Logan, Theodore F
Journal of Clinical Oncology, vol. 36, (no. 15_suppl), pp. e16585, 2018-05-20. | Journal Article
 
NCI 8628: a randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.
Tarhini, Ahmad ATarhini, Ahmad ATarhini, Ahmad AFrankel, PaulFrankel, PaulFrankel, PaulRuel, ChristopherRuel, ChristopherRuel, ChristopherErnstoff, Marc SErnstoff, Marc SErnstoff, Marc SKuzel, Timothy MKuzel, Timothy MKuzel, Timothy MLogan, Theodore FLogan, Theodore FLogan, Theodore FKhushalani, Nikhil IKhushalani, Nikhil IKhushalani, Nikhil ITawbi, Hussein ATawbi, Hussein ATawbi, Hussein AMargolin, Kim AMargolin, Kim AMargolin, Kim AAwasthi, SanjayAwasthi, SanjayAwasthi, SanjayButterfield, Lisa HButterfield, Lisa HButterfield, Lisa HMcDermott, DavidMc Dermott, DavidMcDermott, DavidChen, AliceChen, AliceChen, AliceLara, Primo NLara, Primo NLara, Primo NKirkwood, John MKirkwood, John M and Kirkwood, John M
Cancer, October 10, 2018. | Journal Article
 
PET/CT assessment of tumor perfusion (TP) in metastatic renal cell cancer (RCC) patients (pts) on sunitinib (S) using 62Cu-ETS
Logan, Theodore FLogan, Theodore FLogan, Theodore FLogan, Theodore FFletcher, James WFletcher, James WFletcher, James WFletcher, James WGreen, Mark AGreen, Mark AGreen, Mark AGreen, Mark AEitel, Jacob AaronEitel, Jacob AaronEitel, Jacob AaronEitel, Jacob AaronAlthouse, Sandra KAlthouse, Sandra KAlthouse, Sandra KAlthouse, Sandra KPerkins, Susan MPerkins, Susan MPerkins, Susan MPerkins, Susan MHutchins, GaryHutchins, GaryHutchins, Gary and Hutchins, Gary
Journal of Clinical Oncology, vol. 36, (no. 15_suppl), pp. e16567, 2018-05-20. | Journal Article
 
Prognostic role of BRAF mutation in malignant cutaneous melanoma
Sehdev, AmikarSehdev, AmikarSehdev, AmikarSehdev, AmikarSehdev, AmikarHayden, RossHayden, RossHayden, RossHayden, RossHayden, RossKuhar, Mathew JosephKuhar, Mathew JosephKuhar, Mathew JosephKuhar, Mathew JosephKuhar, Mathew JosephCheng, LiangCheng, LiangCheng, LiangCheng, LiangCheng, LiangWarren, Simon JohnWarren, Simon JohnWarren, Simon JohnWarren, Simon JohnWarren, Simon JohnMark, Lawrence AaronMark, Lawrence AaronMark, Lawrence AaronMark, Lawrence AaronMark, Lawrence AaronWooden, William ArthurWooden, William ArthurWooden, William ArthurWooden, William ArthurWooden, William ArthurSchwartzentruber, Douglas JaySchwartzentruber, Douglas JaySchwartzentruber, Douglas JaySchwartzentruber, Douglas JaySchwartzentruber, Douglas JayLogan, Theodore FLogan, Theodore FLogan, Theodore FLogan, Theodore F and Logan, Theodore F
Journal of Clinical Oncology, vol. 36, (no. 15_suppl), pp. e21599, 2018-05-20. | Journal Article
 
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Chesney, JasonChesney, JasonChesney, JasonChesney, JasonChesney, JasonPuzanov, IgorPuzanov, IgorPuzanov, IgorPuzanov, IgorPuzanov, IgorCollichio, FrancesCollichio, FrancesCollichio, FrancesCollichio, FrancesCollichio, FrancesSingh, ParminderSingh, ParminderSingh, ParminderSingh, ParminderSingh, ParminderMilhem, Mohammed MMilhem, Mohammed MMilhem, Mohammed MMilhem, Mohammed MMilhem, Mohammed MGlaspy, JohnGlaspy, JohnGlaspy, JohnGlaspy, JohnGlaspy, JohnHamid, OmidHamid, OmidHamid, OmidHamid, OmidHamid, OmidRoss, MerrickRoss, MerrickRoss, MerrickRoss, MerrickRoss, MerrickFriedlander, PhilipFriedlander, PhilipFriedlander, PhilipFriedlander, PhilipFriedlander, PhilipGarbe, ClausGarbe, ClausGarbe, ClausGarbe, ClausGarbe, ClausLogan, Theodore FLogan, Theodore FLogan, Theodore FLogan, Theodore FLogan, Theodore FHauschild, AxelHauschild, AxelHauschild, AxelHauschild, AxelHauschild, AxelLebbé, CelesteLebbé, CelesteLebbé, CelesteLebbé, CelesteLebbé, CelesteChen, LisaChen, LisaChen, LisaChen, LisaChen, LisaKim, Jenny JKim, Jenny JKim, Jenny JKim, Jenny JKim, Jenny JGansert, JenniferGansert, JenniferGansert, JenniferGansert, JenniferGansert, JenniferAndtbacka, Robert H IAndtbacka, Robert H IAndtbacka, Robert H IAndtbacka, Robert H IAndtbacka, Robert H IKaufman, Howard LKaufman, Howard LKaufman, Howard LKaufman, Howard L and Kaufman, Howard L
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 36, (no. 17), pp. 1667, 2018-06-10. | Journal Article
 
Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study
Appleman, Leonard JosephNormolle, Daniel PaulLogan, Theodore FMonk, PaulOlencki, ThomasMcDermott, David FErnstoff, Marc SMaranchie, Jodi KathleenParikh, Rahul AtulFriedland, DavidZeh, HerbertLiang, XiaoyanButterfield, Lisa Helene and Lotze, Michael T
Journal of Clinical Oncology, vol. 36, (no. 15_suppl), pp. 4573, 2018-05-20. | Journal Article
 
Sustained Exceptional Response to Poly (ADP-Ribose) Polymerase Inhibition Plus Temozolomide in Metastatic Melanoma With DNA Repair Deficiency
Kiel, Patrick JKiel, Patrick JKiel, Patrick JRadovich, MilanRadovich, MilanRadovich, MilanSchneider, Bryan PSchneider, Bryan PSchneider, Bryan PLogan, Theodore FLogan, Theodore F and Logan, Theodore F
JCO Precision Oncology, (no. 2), pp. 7, 2018-11-00. | Journal Article
 
Targeting autophagy and immunotherapy with hydroxychloroquine and interleukin 2 in patients with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group study
Appleman, Leonard JosephLogan, Theodore FNormolle, Daniel PaulErnstoff, Marc SParikh, Rahul AtulMcDermott, David FMonk, PaulOlencki, ThomasFriedland, DavidMaranchie, Jodi KathleenButterfield, Lisa HeleneLiang, Xiaoyan and Lotze, Michael T
Journal of Clinical Oncology, vol. 36, (no. 5_suppl), pp. 106, 2018-02-10. | Journal Article
2017
Abstract 3827: NCI 8628 - A randomized phase II study of Ziv-aflibercept (Z) and high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV melanoma
Tarhini, Ahmad ATarhini, Ahmad AFrankel, Paul HFrankel, Paul HRuel, ChristopherRuel, ChristopherErnstoff, Marc SErnstoff, Marc SKuzel, Timothy MKuzel, Timothy MLogan, Theodore FLogan, Theodore FKhushalani, Nikhil IKhushalani, Nikhil ITawbi, Hussein ATawbi, Hussein AMargolin, Kim AMargolin, Kim AAwasthi, SanjayAwasthi, SanjayMcDermott, David FMcDermott, David FChen, AliceChen, AliceLara, Primo NLara, Primo NKirkwood, John M and Kirkwood, John M
Cancer Research, vol. 77, (no. 13 Supplement), pp. 3827, 2017-07-01. | Journal Article
 
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM SM registry
Curti, BrendanCurti, BrendanDaniels, Gregory ADaniels, Gregory AMcDermott, David FMcDermott, David FClark, Joseph IClark, Joseph IKaufman, Howard LKaufman, Howard LLogan, Theodore FLogan, Theodore FSingh, JatinderSingh, JatinderKaur, MeenuKaur, MeenuLuna, Theresa LLuna, Theresa LGregory, NancyGregory, NancyMorse, Michael AMorse, Michael AWong, Michael K KWong, Michael K KDutcher, Janice P and Dutcher, Janice P
Journal for immunotherapy of cancer, vol. 5, (no. 1), pp. 102, 2017-Dec-19. | Journal Article
 
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry
Curti, BrendanCurti, BrendanCurti, BrendanCurti, BrendanDaniels, Gregory ADaniels, Gregory ADaniels, GregoryDaniels, Gregory AMcDermott, David FMcDermott, DavidMcDermott, David FMc Dermott, David FClark, Joseph IClark, JosephClark, Joseph IClark, Joseph IKaufman, Howard LKaufman, HowardKaufman, Howard LKaufman, Howard LLogan, Theodore FLogan, Theodore FLogan, Theodore FLogan, TheodoreSingh, JatinderSingh, JatinderSingh, JatinderSingh, JatinderKaur, MeenuKaur, MeenuKaur, MeenuKaur, MeenuLuna, TheresaLuna, Theresa LLuna, Theresa LLuna, Theresa LGregory, NancyGregory, NancyGregory, NancyGregory, NancyMorse, Michael AMorse, Michael AMorse, MichaelMorse, Michael AWong, Michael K. KWong, Michael K KWong, Michael K. KWong, MichaelDutcher, Janice PDutcher, JaniceDutcher, Janice P and Dutcher, Janice P
Journal for ImmunoTherapy of Cancer, vol. 5, (no. 1), pp. 102, 2017-12-00. | Journal Article
 
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Segal, Neil HSegal, Neil HSegal, Neil HSegal, Neil HLogan, Theodore FLogan, Theodore FLogan, Theodore FLogan, Theodore FStephen, Hodi FHodi, F StephenStephen, Hodi FHodi, F StephenMcDermott, DavidMcDermott, DavidMc Dermott, DavidMcDermott, DavidMelero, IgnacioMelero, IgnacioHamid, OmidHamid, OmidSchmidt, HenrikSchmidt, HenrikSchmidt, HenrikSchmidt, HenrikRobert, CarolineRobert, CarolineRobert, CarolineRobert, CarolineChiarion-Sileni, VannaChiarion-Sileni, VannaAscierto, Paolo AAscierto, Paolo AAscierto, Paolo AAscierto, Paolo AMaio, MicheleMaio, MicheleMaio, MicheleMaio, MicheleUrba, Walter JUrba, Walter JUrba, Walter JUrba, Walter JGangadhar, Tara CGangadhar, Tara CGangadhar, Tara CGangadhar, Tara CSuryawanshi, SatyendraSuryawanshi, SatyendraNeely, JaclynNeely, JaclynJure-Kunkel, MariaJure-Kunkel, MariaJure-Kunkel, MariaJure-Kunkel, MariaKrishnan, SubaKrishnan, SubaHolbrook, KohrtHolbrook, KohrtKohrt, HolbrookKohrt, HolbrookSznol, MarioSznol, MarioLevy, RonaldLevy, RonaldLevy, Ronald and Levy, Ronald
Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 23, (no. 8), pp. 1936, 2017-04-15. | Journal Article
 
Safety and preliminary activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma (mRCC): A cytokine working group study
Appleman, Leonard JosephLogan, Theodore FNormolle, Daniel PaulErnstoff, Marc SParikh, Rahul AtulMcDermott, David FMonk, PaulOlencki, ThomasFriedland, DavidMaranchie, Jodi Kathleen and Lotze, Michael T
Journal of Clinical Oncology, vol. 35, (no. 6_suppl), pp. 440, 2017-02-20. | Journal Article
2016
A phase I/Ib, open-label, dose-finding study to evaluate safety, pharmacodynamics, and efficacy of pembrolizumab (MK-3475) in combination with vorinostat in patients with advanced renal or urothelial cell carcinoma
Pili, RobertoPili, RobertoQuinn, DavidQuinn, DavidHahn, Noah MHahn, Noah MAlbany, CostantineAlbany, CostantineLogan, Theodore FLogan, Theodore FDrake, Charles G and Drake, Charles G
Journal of Clinical Oncology, vol. 34, (no. 15_suppl), pp. TPS4581, 2016-05-20. | Journal Article
 
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
Alva, AjjaiAlva, AjjaiAlva, AjjaiDaniels, GregoryDaniels, Gregory ADaniels, GregoryWong, MichaelWong, Michael K. KWong, MichaelKaufman, HowardKaufman, HowardKaufman, Howard LMorse, MichaelMorse, Michael AMorse, MichaelMcDermott, David FMcDermott, DavidMcdermott, DavidMc Dermott, David FClark, Joseph IClark, JosephClark, JosephAgarwala, SanjivAgarwala, SanjivAgarwala, Sanjiv SMiletello, GeraldMiletello, GeraldMiletello, GeraldLogan, TheodoreLogan, Theodore FLogan, TheodoreHauke, RalphHauke, RalphHauke, Ralph JCurti, BrendanCurti, BrendanCurti, BrendanKirkwood, JohnKirkwood, JohnKirkwood, John MGonzalez, ReneGonzalez, ReneGonzalez, ReneAmin, AsimAmin, AsimAmin, AsimFishman, MayerFishman, MayerFishman, MayerAgarwal, NeerajAgarwal, NeerajAgarwal, NeerajLowder, JamesLowder, JamesLowder, James NHua, HongHua, HongHua, HongAung, SandraAung, SandraAung, SandraDutcher, Janice PDutcher, Janice and Dutcher, Janice
Cancer Immunology, Immunotherapy, vol. 65, (no. 12), pp. 1533-1544, Dec 2016. | Journal Article
 
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Armstrong, Andrew JArmstrong, Andrew JArmstrong, Andrew JHalabi, SusanHalabi, SusanHalabi, SusanEisen, TimEisen, TimEisen, TimBroderick, SamuelBroderick, SamuelBroderick, SamuelStadler, Walter MStadler, Walter MStadler, Walter MJones, Robert JJones, Robert JJones, Robert JGarcia, Jorge AGarcia, Jorge AGarcia, Jorge AVaishampayan, Ulka NVaishampayan, Ulka NVaishampayan, Ulka NPicus, JoelPicus, JoelPicus, JoelHawkins, Robert EHawkins, Robert EHawkins, Robert EHainsworth, John DHainsworth, John DHainsworth, John DKollmannsberger, Christian KKollmannsberger, Christian KKollmannsberger, Christian KLogan, Theodore FLogan, Theodore FLogan, Theodore FPuzanov, IgorPuzanov, IgorPuzanov, IgorPickering, Lisa MPickering, Lisa MPickering, Lisa MRyan, Christopher WRyan, Christopher WRyan, Christopher WProtheroe, AndrewProtheroe, AndrewProtheroe, AndrewLusk, Christine MLusk, Christine MLusk, Christine MOberg, SadieOberg, SadieOberg, SadieGeorge, Daniel JGeorge, Daniel J and George, Daniel J
The Lancet. Oncology, vol. 17, (no. 3), pp. 378-388, March 2016. | Journal Article
 
Results From an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
Segal, Neil HLogan, Theodore FHodi, F StephenMc Dermott, David FMelero, IgnacioHamid, OmidSchmidt, HenrikRobert, CarolineChiarion-Sileni, VannaAscierto, Paolo AMaio, MicheleUrba, Walter JGangadhar, Tara CSuryawanshi, SatyendraNeely, JaclynJure-Kunkel, MariaKrishnan, SubaKohrt, Holbrook ESznol, Mario and Levy, Ronald
Clinical cancer research : an official journal of the American Association for Cancer Research, October 18, 2016. | Journal Article
 
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber, Jeffrey SWeber, Jeffrey SWeber, Jeffrey SGibney, GeoffGibney, GeoffGibney, GeoffSullivan, Ryan JSullivan, Ryan JSullivan, Ryan JSosman, Jeffrey ASosman, Jeffrey ASosman, Jeffrey ASlingluff, Craig LSlingluff, Craig LSlingluff, Craig LLawrence, Donald PLawrence, Donald PLawrence, Donald PLogan, Theodore FLogan, Theodore FLogan, Theodore FSchuchter, Lynn MSchuchter, Lynn MSchuchter, Lynn MNair, SureshNair, SureshNair, SureshFecher, LeslieFecher, LeslieFecher, LeslieBuchbinder, Elizabeth IBuchbinder, Elizabeth IBuchbinder, Elizabeth IBerghorn, ElmerBerghorn, ElmerBerghorn, ElmerRuisi, MaryRuisi, MaryRuisi, MaryKong, GeorgeKong, GeorgeKong, GeorgeJiang, JoelJiang, JoelJiang, JoelHorak, ChristineHorak, ChristineHorak, ChristineHodi, F SHodi, F Stephen and Hodi, F S
The Lancet. Oncology, vol. 17, (no. 7), pp. 943-955, July 2016. | Journal Article